Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018
SUMMARY
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 4, 1, 7 and 3 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Cardiovascular, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myelofibrosis, Alopecia, Atopic Dermatitis (Atopic Eczema), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hematological Tumor, Leukemias, Myeloproliferative Disorders, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular/Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 4, 1, 7 and 3 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Cardiovascular, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myelofibrosis, Alopecia, Atopic Dermatitis (Atopic Eczema), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hematological Tumor, Leukemias, Myeloproliferative Disorders, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular/Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celgene Corp
Celon Pharma SA
CJ HealthCare Corp
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
NMS Group SpA
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tragara Pharmaceuticals Inc
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
APL-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-13503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHZ-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPL-407105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
jaktinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-317461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting
Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease
Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018
Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting
Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 01, 2018: CTI BioPharma announces the continuation of PAC203 Study following interim data review
Sep 28, 2018: Concert revises Phase lla trial design to add new CTP-543 dose
Sep 13, 2018: Incyte announces positive data from phase 2b trial of Ruxolitinib cream in patients with atopic dermatitis
Sep 10, 2018: Lilly to Showcase Olumiant new data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, furthering innovation for patients with complex dermatological conditions
Jul 19, 2018: Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
Jul 18, 2018: CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
Jul 02, 2018: CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Jun 21, 2018: Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi) in Steroid-Refractory Acute Graft-Versus-Host Disease
Jun 21, 2018: Incyte to Present Data on Jakafi at 2018 Investor and Analyst Event
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celgene Corp
Celon Pharma SA
CJ HealthCare Corp
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
NMS Group SpA
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tragara Pharmaceuticals Inc
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
APL-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-13503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHZ-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPL-407105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
jaktinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-317461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting
Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease
Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018
Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting
Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 01, 2018: CTI BioPharma announces the continuation of PAC203 Study following interim data review
Sep 28, 2018: Concert revises Phase lla trial design to add new CTP-543 dose
Sep 13, 2018: Incyte announces positive data from phase 2b trial of Ruxolitinib cream in patients with atopic dermatitis
Sep 10, 2018: Lilly to Showcase Olumiant new data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, furthering innovation for patients with complex dermatological conditions
Jul 19, 2018: Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
Jul 18, 2018: CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
Jul 02, 2018: CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Jun 21, 2018: Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi) in Steroid-Refractory Acute Graft-Versus-Host Disease
Jun 21, 2018: Incyte to Present Data on Jakafi at 2018 Investor and Analyst Event
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aerie Pharmaceuticals Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Celon Pharma SA, H2 2018
Pipeline by CJ HealthCare Corp, H2 2018
Pipeline by Concert Pharmaceuticals Inc, H2 2018
Pipeline by CTI BioPharma Corp, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by NMS Group SpA, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by NS Pharma Inc, H2 2018
Pipeline by Simcere Pharmaceutical Group, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Pipeline by Tragara Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aerie Pharmaceuticals Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Celon Pharma SA, H2 2018
Pipeline by CJ HealthCare Corp, H2 2018
Pipeline by Concert Pharmaceuticals Inc, H2 2018
Pipeline by CTI BioPharma Corp, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by NMS Group SpA, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by NS Pharma Inc, H2 2018
Pipeline by Simcere Pharmaceutical Group, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Pipeline by Tragara Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
COMPANIES MENTIONED
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celgene Corp
Celon Pharma SA
CJ HealthCare Corp
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
NMS Group SpA
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tragara Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
COMPANIES MENTIONED
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celgene Corp
Celon Pharma SA
CJ HealthCare Corp
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
NMS Group SpA
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tragara Pharmaceuticals Inc
